Report Overview
About Myocardial Infarction Drugs
Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.
Technavios analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Bayer HealthCare
• Eli Lilly
• Novartis
• Pfizer
• Sanofi
Other prominent vendors
• advanceCOR
• Armaron Bio
• Athersys
• BioVascular
• BMS
• Caladrius
• Capricor
• CSL Behring
• GNT Pharma
• GSK
• Ischemix
• Mesoblast
• NeuroVive
• Osiris Therapeutics
• PledPharma
• RegeneRx
• Teva Pharmaceuticals
• TiGenix
• US Stem Cell
• Ventrix
Market driver
• Growing older population
• For a full, detailed list, view our report
Market challenge
• Alternative therapies
• For a full, detailed list, view our report
Market trend
• Growing awareness of disease
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
Table Of Contents
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Disease overview
Types of myocardial infarction
Pathophysiology
Risk factors
Diagnosis
Management
PART 06: Epidemiology and economic burden
Burden of disease
PART 07: Pipeline analysis
Canakinumab
MyoCell
MultiStem therapy
CLBS10
Prochymal
Revascor
CicloMulsion
PP-099
NP202
CAP-1002
Revacept
CSL112
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by drug class
Beta blockers
ACE inhibitors
ARBs
Vasodilators
Antithrombotic agents
Thrombolytics
Glycoprotein IIb/IIIa inhibitors
Anti-dyslipidemic drugs
Calcium channel blockers
Analgesics
PART 10: Market segmentation by EKG appearance
NSTEMI
STEMI
PART 11: Market segmentation by type
Brand-name drugs
Generic drugs
PART 12: Geographical segmentation
Global myocardial infarction drugs market segmentation by geography 2015-2020
Myocardial infarction drugs market in Americas
Myocardial infarction drugs market in EMEA
Myocardial infarction drugs market in APAC
PART 13: Market drivers
Increase in older population
Sedentary lifestyle
Rise in obesity
High prevalence of chronic conditions
PART 14: Impact of drivers
PART 15: Market challenges
Delayed diagnosis
Alternative therapies
Extensive use of generics
PART 16: Impact of drivers and challenges
PART 17: Market trends
Growing awareness of disease
Strategic alliances
Increased R&D
Prevalent use of stent grafts
PART 18: Vendor landscape
Competitive scenario
AstraZeneca
Bayer HealthCare
Eli Lilly
Novartis
Pfizer
Sanofi
Other prominent vendors
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for myocardial infarction drugs
Exhibit 03: Pathophysiology of myocardial infarction
Exhibit 04: Risk factors of myocardial infarction
Exhibit 05: Diagnostic techniques for myocardial infarction
Exhibit 06: Treatment options for myocardial infarction
Exhibit 07: Projected prevalence of CVDs in US
Exhibit 08: Projected economic burden for CVDs in US
Exhibit 09: Pipeline portfolio: Myocardial infarction
Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis
Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
Exhibit 28: AstraZeneca: Key takeaways
Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
Exhibit 31: Bayer HealthCare: Key takeaways
Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
Exhibit 35: Eli Lilly: Key takeaways
Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
Exhibit 38: Novartis: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
Exhibit 46: Sanofi: Key takeaways